Patents by Inventor Michael J. Rosinko

Michael J. Rosinko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12144964
    Abstract: Embodiments are directed to portable infusion devices, systems, and methods of using the same for dispensing materials. In some cases, the devices, systems and methods may be used for infusing a material such as medicament, e.g., insulin, into a body in need thereof.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: November 19, 2024
    Assignee: Tandem Diabetes Care, Inc
    Inventors: Paul M. DiPerna, Michael J. Rosinko, Geoffrey A. Kruse, Thomas R. Ulrich, Christopher Dabrow, Mark Williamson, Brian Bureson, Kathryn Rieger
  • Patent number: 12115338
    Abstract: Certain embodiments provide multi-medicament infusion systems for preventing the cross-channeling of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The infusion pump can have an inductively chargeable battery assembly that can be charged by an inductive charging pad.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: October 15, 2024
    Assignee: Beta Bionics, Inc.
    Inventors: David Matthew Henderson, Todd S. Ray, Michael J. Rosinko, Bryan Dale Knodel
  • Patent number: 12102795
    Abstract: Enhanced confirmations for programming of touchscreen infusion pumps reduce the likelihood of users confirming pump parameters that have been mistakenly programmed. Following programming of a given pump parameter, an icon or image intuitively related to the pump parameter can be displayed on the touchscreen. To confirm programming of the parameter, the user can be required to trace the icon on the touchscreen. The user will therefore necessarily associate the confirmation step with the parameter being programmed and be far more likely to realize if a mistake has been made because the user was intending to program a different parameter than with simple confirmations involving the press of a confirmation button.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: October 1, 2024
    Assignee: Tandem Diabetes Care, Inc.
    Inventor: Michael J. Rosinko
  • Patent number: 12093681
    Abstract: An ambulatory medicament device can generate a dose control signal for delivery of medicament to a subject and secure at least some functionality of a user interface of the ambulatory medicament device. The ambulatory medicament device can have a locked state that restricts modification of at least one control parameter. The ambulatory medicament device can have an unlocked state that allows modification of at least one control parameter. The ambulatory medicament device can accept a user input of a security code that is validated against a passcode to enter from the locked state to the unlocked state.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: September 17, 2024
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Publication number: 20240299655
    Abstract: Embodiments are directed to portable infusion devices, systems, and methods of using the same for dispensing materials. In some cases, the devices, systems and methods may be used for infusing a material such as medicament, e.g., insulin, into a body in need thereof.
    Type: Application
    Filed: May 20, 2024
    Publication date: September 12, 2024
    Applicant: Tandem Diabetes Care, Inc.
    Inventors: Paul M. DiPerna, Michael J. Rosinko, Geoffrey A. Kruse, Thomas R. Ulrich, Christopher Dabrow, Mark Williamson, Brian Bureson, Kathryn Rieger
  • Publication number: 20240256267
    Abstract: An ambulatory medical device can detect a device condition and determine if the device condition satisfies a set of normal operating parameters. If the normal operating parameters are not satisfied, the ambulatory medical device can determine if the device condition stratifies a set of minimum operating parameters. If the minimum operating parameters are satisfied, the ambulatory medical device can maintain a delivery of therapy to a subject and generate an alert based on the device condition.
    Type: Application
    Filed: February 14, 2024
    Publication date: August 1, 2024
    Applicant: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. EI-Khatib, David Chi-Wai Lim
  • Patent number: 12042627
    Abstract: Embodiments are directed to portable infusion devices, systems, and methods of using the same for dispensing materials. In some cases, the devices, systems and methods may be used for infusing a material such as medicament, e.g., insulin, into a body in need thereof.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: July 23, 2024
    Assignee: Tandem Diabetes Care, Inc.
    Inventors: Paul M. DiPerna, Michael J. Rosinko, Geoffrey A. Kruse, Thomas R. Ulrich, Christopher Dabrow, Mark Williamson, Brian Bureson, Kathryn Rieger
  • Publication number: 20240173475
    Abstract: Ambulatory medicament devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and methods can implement one or more features that improve the user experience, by modifying delivery of therapy to a subject after determining that a possible occlusion exists in a medicament delivery system, monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device and annunciating alarm condition when necessary, selectively muting alarm annunciations while a Do Not Disturb mode is activated, implementing various power saving modes to save power, controlling operation of the device and medicament delivery based on the user gesture controls, and controlling medicament delivery based on a condition of the ambulatory medicament device.
    Type: Application
    Filed: February 2, 2024
    Publication date: May 30, 2024
    Applicant: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Firas H. El-Khatib, Himanshu Patel
  • Patent number: 11957876
    Abstract: An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: April 16, 2024
    Assignee: BETA BIONICS, INC.
    Inventors: Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
  • Patent number: 11941392
    Abstract: An ambulatory medical device can detect a device condition and determine if the device condition satisfies a set of normal operating parameters. If the normal operating parameters are not satisfied, the ambulatory medical device can determine if the device condition stratifies a set of minimum operating parameters. If the minimum operating parameters are satisfied, the ambulatory medical device can maintain a delivery of therapy to a subject and generate an alert based on the device condition.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: March 26, 2024
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, David Chi-Wai Lim
  • Patent number: 11925788
    Abstract: Ambulatory medicament devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and methods can implement one or more features that improve the user experience, by modifying delivery of therapy to a subject after determining that a possible occlusion exists in a medicament delivery system, monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device and annunciating alarm condition when necessary, selectively muting alarm annunciations while a Do Not Disturb mode is activated, implementing various power saving modes to save power, controlling operation of the device and medicament delivery based on the user gesture controls, and controlling medicament delivery based on a condition of the ambulatory medicament device.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Firas H. El-Khatib, Himanshu Patel
  • Publication number: 20240024578
    Abstract: A glucose level control system may be configured to determine that certain status information fails to satisfy at least one of a plurality of safety thresholds. The system may receive status information, which may include device information pertaining to a condition of the ambulatory medicament device and/or subject information pertaining to a condition of a subject. The system can determine that the status information fails to satisfy the safety threshold(s). In response to determining that the status information fails to satisfy the at least one of a plurality of safety thresholds, the system can automatically execute a distress action. Example safety thresholds include a glucose level of a subject being less than a minimum threshold, a glucose level of a subject being greater than a maximum threshold, a movement of the subject being less than a minimum movement threshold for a threshold amount of time, and/or other safety thresholds.
    Type: Application
    Filed: July 18, 2023
    Publication date: January 25, 2024
    Inventors: Himanshu Patel, Michael J. Rosinko, Firasd H. El-Khatib, Edward R. Damiano
  • Publication number: 20230405224
    Abstract: A glucose level control system may be configured to determine a recommended medicament dose based at least in part on a subject's therapy data and/or user-specified medicament related inputs. The therapy data may include glucose level data and medicament delivery data. The user-specified medicament related inputs may include qualitative meal announcements. For example, the user can specify that the subject consumed a small, medium, or large meal. The glucose level control system may be configured to output an indication of the recommended medicament dose to a display. The glucose level control system may be configured to output a dose control signal to preconfigure a smart pen to deliver the recommended medicament dose. The glucose level control system may be configured to generate an alert if it determines, based at least in part on glucose level data and/or medicament delivery data associated with the subject, that trigger criteria have been satisfied.
    Type: Application
    Filed: April 6, 2023
    Publication date: December 21, 2023
    Inventors: Michael J. Rosinko, Himanshu Patel, Firas H. El-Khatib
  • Publication number: 20230381413
    Abstract: A glucose level control system may be configured to adapt a time-segmented basal dose. The glucose level control system may determine the first basal dose based at least in part on a user-specified basal dose and/or total daily dose value. The first basal dose may also be based on a basal dose received from the memory of the glucose level control system or from a remote storage device. The first basal dose may be administered during a first time period. The glucose level control system may adapt the first basal dose to a second basal dose for a second therapy period. The glucose level control system may adapt the second basal dose based on a difference between a predicted and measured glucose level.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 30, 2023
    Inventors: Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
  • Patent number: 11803367
    Abstract: Systems and methods are disclosed herein for monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device. The ambulatory medical device can have a touchscreen display user interface to receive input signals from a user and display alarm conditions associated with the status of an ambulatory medical device or health condition of a subject. The disclosed methods and systems can determine whether status information received from a monitoring system interface satisfies an alarm condition for the ambulatory medicament device or for the subject. If the status information satisfies an alarm condition, the touchscreen user interface can display one or more alarm status indicators corresponding to the alarm condition. The user can activate a therapy change interface on the touchscreen display and modify a control parameter of the ambulatory medical device that controls the therapy delivery to the subject.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: October 31, 2023
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Justin P. Brown, Bryan Dale Knodel, Himanshu Patel
  • Publication number: 20230337949
    Abstract: A glucose level control system may be configured to determine that certain status information fails to satisfy at least one of a plurality of safety thresholds. The system may receive status information, which may include device information pertaining to a condition of the ambulatory medicament device and/or subject information pertaining to a condition of a subject. The system can determine that the status information fails to satisfy the safety threshold(s). In response to determining that the status information fails to satisfy the at least one of a plurality of safety thresholds, the system can automatically execute a distress action. Example safety thresholds include a glucose level of a subject being less than a minimum threshold, a glucose level of a subject being greater than a maximum threshold, a movement of the subject being less than a minimum movement threshold for a threshold amount of time, and/or other safety thresholds.
    Type: Application
    Filed: April 19, 2023
    Publication date: October 26, 2023
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Patent number: D1022185
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: April 9, 2024
    Inventors: Bryan Dale Knodel, David Matthew Henderson, Edward R. Damiano, Michael J. Rosinko
  • Patent number: D1031975
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: June 18, 2024
    Assignee: Beta Bionics, Inc.
    Inventors: Bryan Dale Knodel, David Matthew Henderson, Edward R. Damiano, Michael J. Rosinko
  • Patent number: D1032623
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: June 25, 2024
    Assignee: Beta Bionics, Inc.
    Inventors: David Chi-Wai Lim, Edward R. Damiano, Michael J. Rosinko, Mads Henrik Dall
  • Patent number: D1032624
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: June 25, 2024
    Assignee: Beta Bionics, Inc.
    Inventors: David Chi-Wai Lim, Edward R. Damiano, Michael J. Rosinko, Mads Henrik Dall